Pharmacokinetic-pharmacodynamic models for inhaled anaesthetics

被引:0
|
作者
Kreuer, S. [1 ]
Bruhn, J.
Wilhelm, W.
Bouillon, T.
机构
[1] Univ Klinikum Saarlandes, Klin Anasthesiol Intensivmed & Schmerztherapie, Homburg, Germany
[2] Radboud Univ Nijmegen Med Ctr, Dept Anaesthesiol, Nijmegen, Netherlands
[3] Klinikum St Marien Hosp, Klin Anasthesiol & Operat Intensivmed, Lunen, Germany
[4] Univ Bern, Inselspital, Klin & Poliklin Anasthesiol, CH-3010 Bern, Switzerland
来源
ANAESTHESIST | 2007年 / 56卷 / 06期
关键词
volatile anaesthetics; N2O; opioids; distribution coefficient; k(e0) value; EEG index;
D O I
10.1007/s00101-007-1188-7
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Pharmacokinetic models can be differentiated into two groups: physiological-based models and empirical models. Traditionally the pharmacokinetics of volatile anaesthetics are described using physiological-based models together with the respective tissue-blood distribution coefficients. The compartments of the empirical model have no anatomical equivalents and are merely the product of the mathematical procedure for parameter estimation. The end expiratory concentration of volatile anaesthetics is approximately equal to the arterial concentration and, therefore, the description of the transition between plasma and effect site for volatile anaesthetics plays a central role. The most important parameter here is the k(e0) value which is a time constant and describes the time delay for the transition from the central compartment to the calculated effect compartment. The k(e0) values for sevoflurane and isoflurane are the same but the concentration balance between the end-tidal concentration and the effect compartment occurs twice as quickly with desflurane. In clinical practice volatile anaesthetics are normally combined with N2O and/or opioids. This results in an additive interaction between volatile anaesthetics and N2O but a synergistic interaction of volatile anaesthetics with opioids. However, there are relatively few investigations on the interactions between the clinically widely used combination of volatile anaesthetics, N2O and opioids.
引用
收藏
页码:538 / 556
页数:19
相关论文
共 50 条
  • [21] AN APPLICATION OF BAYESIAN POPULATION PHARMACOKINETIC-PHARMACODYNAMIC MODELS TO DOSE RECOMMENDATION
    WAKEFIELD, J
    RACINEPOON, A
    [J]. STATISTICS IN MEDICINE, 1995, 14 (9-10) : 971 - 986
  • [22] Pharmacokinetic-pharmacodynamic models that incorporate drug-target binding kinetics
    Daryaee, Fereidoon
    Tonge, Peter J.
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2019, 50 : 120 - 127
  • [23] Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic-pharmacodynamic relationships
    Danysz, Wojciech
    Flik, Gunnar
    McCreary, Andrew
    Tober, Carsten
    Dimpfel, Wilfried
    Bizot, Jean C.
    Kostrzewa, Richard
    Brown, Russell W.
    Jatzke, Claudia C.
    Greco, Sergio
    Jenssen, Ann-Kristin
    Parsons, Christopher G.
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (09) : 1221 - 1238
  • [24] Incorporating Physiological and Biochemical Mechanisms into Pharmacokinetic-Pharmacodynamic Models: A Conceptual Framework
    Dahl, Svein G.
    Aarons, Leon
    Gundert-Remy, Ursula
    Karlsson, Mats O.
    Schneider, Yves-Jacques
    Steimer, Jean-Louis
    Troconiz, Inaki F.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2010, 106 (01) : 2 - 12
  • [25] CONCEPTS AND USEFULNESS OF PHARMACOKINETIC-PHARMACODYNAMIC MODELING
    HOLFORD, NHG
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1990, 4 : S93 - S101
  • [26] Pharmacokinetic-pharmacodynamic model for educational simulations
    van Meurs, WL
    Nikkelen, E
    Good, ML
    [J]. IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, 1998, 45 (05) : 582 - 590
  • [27] Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - Dealing with unbalanced designs
    Ogungbenro, Kayode
    Gueorguieva, Ivelina
    Majid, Oneeb
    Graham, Gordon
    Aarons, Leon
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2007, 34 (03) : 313 - 331
  • [28] APPLICATION OF PHARMACOKINETIC-PHARMACODYNAMIC MODELING TO ANALGESIA
    INTURRISI, CE
    COLBURN, WA
    [J]. ADVANCES IN PAIN RESEARCH AND THERAPY, 1986, 8 : 441 - 452
  • [29] PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS OF MORPHINE IN NEONATES
    CHAY, PCW
    DUFFY, BJ
    WALKER, JS
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (03) : 334 - 342
  • [30] Pharmacokinetic-pharmacodynamic modelling of danofloxacin in turkeys
    Haritova, A. M.
    Rusenova, N. V.
    Parvanov, P. R.
    Lashev, L. D.
    Fink-Gremmels, J.
    [J]. VETERINARY RESEARCH COMMUNICATIONS, 2006, 30 (07) : 775 - 789